Azenta, Inc. (AZTA) Appoints Dipal Doshi to its Board

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024.

"Mr. Doshi is an extraordinary leader who brings significant experience in the biotechnology and pharmaceutical industries," said John Marotta, President and CEO of Azenta. "His experience in strategy, operational and commercial growth, and perspective as a current public company CEO make him a perfect fit for our Board.

"I am excited to be joining Azenta at a critical time in their evolution," said Dipal Doshi. "Azenta's strong market leadership position and its commitment to growth and innovation is clear. I look forward to collaborating with the Board and the leadership team to help shape the company's future and make a meaningful impact."

You May Also Be Interested In

• Richard Lowenthal resigns from ARS Pharmaceuticals board
• Boxabl completes SPAC merger, begins trading on Nasdaq at $3.5B value
• Meritage Hospitality posts Q2 loss amid restructuring charges